Innoviva, Inc. (INVA) financial statements and ratios from SEC XBRL: revenue $0.4B (TTM), net margin 65.9%, revenue growth 14.7% YoY, P/E 4.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $411.33M |
| Revenue (TTM) | $0.4B |
| Net Margin | 65.9% |
| Operating Margin (TTM) | 35.5% |
| Net Debt / EBITDA | -0.8 |
| Revenue Growth (YoY) | 14.7% |
| EPS Growth (YoY) | 986.5% |
| FCF Growth (YoY) | 3.9% |
| P/E Ratio | 4.0 |
| EV / EBITDA | 7.5 |
| Price / Book | 1.23 |
| Price / Sales | 3.60 |
| FCF Yield | 19.5% |
| Altman Z-Score | 3.34 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
INVA overview · INVA earnings · INVA KPIs · INVA documents · INVA ownership · INVA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.